Ironwood Pharmaceuticals Inc (IRWD)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

100 SUMMER STREET, SUITE 2300 BOSTON, MA 02110

Ironwood Pharmaceuticals, Inc. discovers, develops, and commercializes medicines targeting therapeutic needs. The company is developing Linaclotide, a first-in-class compound that is in confirmatory Phase III clinical trials for the treatment of irritable bowel syndrome with constipation, chronic constipation, and other lower gastrointestinal conditions. It also focuses on one Phase I pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. The company has a collaboration agreement with Forest Laboratories, Inc. to jointly develop and commercialize linaclotide in North America; a license agreement with Almirall, S.A. to develop and commercialize linaclotide in Europe; a license agreement with Astellas Pharma Inc. that provides Astellas Pharma with the right to develop and commercialize linaclotide in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Data as of 2020-09-12
Market Cap1.557 Billion Shares Outstanding159.978 Million Avg 30-day Volume1.638 Million
P/E Ratio15.5 Dividend Yield EPS0.62
Price/Sales3.647 Price cash flow ratio12.1 Price free cash flow ratio13.0
Book Value-0.23 Price to Tangible Book-41.67 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.259524
BETA1.41646 52-week High/Low14.1 / 7.91 Stddev0.118802
View SEC Filings from IRWD instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 3 -33.33% 2 (0.13%) 3 (0.19%) -33.33%
Funds Holding: 201 194 3.61% 64 (4.17%) 64 (4.09%) 0.0%
13F shares: 175.653 Million 176.059 Million -0.23% 74.386 Million 70.905 Million 4.91%
% Ownership 46.6727 44.4896 4.91%
New Positions: 29 29 0.0% 12 10 20.0%
Increased Positions 87 63 38.1% 33 26 26.92%
Closed Positions 19 31 -38.71% 11 13 -15.38%
Reduced Positions 53 69 -23.19% 15 25 -40.0%
Total Calls 1.319 Million 676.556 Thousand 95.02% 646.4 Thousand 40 Thousand 1516.0%
Total Puts 623.45 Thousand 598.04 Thousand 4.25% 545.6 Thousand 547.8 Thousand -0.4%
PUT/CALL Ratio 0.47 0.88 -46.59% 0.84 13.7 -93.87%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding IRWD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IRWD BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

9.2 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DREYFUS ANDREW

  • Director
112,003 2020-09-15 5

MCHUGH JULIE

  • Director
123,107 2020-09-08 2

MACDONALD KELLY CHIEF ACCOUNTING OFFICER

  • Officer
118,552 2020-08-17 6

RICKARD JASON SVP, CHIEF OPERATING OFFICER

  • Officer
235,776 2020-08-17 3

OLANOFF LAWRENCE S

  • Director
68,629 2020-06-10 2

CURRIE MARK G

  • Director
570,992 2020-06-03 4

OWENS EDWARD P

  • Director
243,954 2020-06-03 1

DUANE JON R

  • Director
47,421 2020-06-03 1

KESSLER MARLA L

  • Director
47,421 2020-06-03 1

MOUKHEIBIR CATHERINE

  • Director
47,421 2020-06-03 1

MCCOURT THOMAS A PRESIDENT

  • Officer
319,847 2020-05-11 5

MALLON MARK CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
501,280 2020-05-11 3

KILROY CONOR SVP, GC & SECRETARY

  • Officer
128,921 2020-05-11 3

SHETZLINE MICHAEL CMO, SVP & HEAD OF DRUG DEVT.

  • Officer
107,046 2020-04-24 2

CONSYLMAN GINA SVP, CFO & TREASURER

  • Officer
271,114 2020-02-27 4

GILBERT HALLEY E CHIEF ADMIN OFFICER & SVP

  • Officer
265,991 2020-02-21 3

MCGUIRE TERRANCE

  • Director
144,373 2019-04-01 0

HECHT PETER M CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2019-04-01 0

FANUCCI MARSHA

  • Director
132,663 2019-04-01 0

WILLIAMS DOUGLAS E

  • Director
87,800 2019-04-01 0

SCHULMAN AMY W

  • Director
38,242 2019-04-01 0

HUYETT WILLIAM CHIEF OPERATING OFFICER

  • Officer
27,546 2019-04-01 0

WALSH CHRISTOPHER T PHD

  • Director
374,525 2017-03-15 0

GRANEY THOMAS CHIEF FINANCIAL OFFICER

  • Officer
42,013 2017-02-27 0

ROBERTS BRYAN E

  • Director
123,978 2015-06-15 0

CONRADES GEORGE H

  • Director
635,976 2015-06-03 0

EBERSMAN DAVID A

  • Director
101,233 2015-03-13 0

COOK JOSEPH C JR

  • Director
328,080 2015-03-11 0

HIGGINS MICHAEL J CHIEF OPERATING OFFICER

  • Officer
329,102 2014-12-23 0

SHAW DAVID EVANS

  • Director
393,455 2014-03-14 0

FMR LLC

FIL LTD

  • EDWARD C. JOHNSON 3DEDWARD C. JOHNSON 3D
No longer subject to file 2013-03-28 0

VENROCK ASSOCIATES

VENROCK ASSOCIATES II LP

VENROCK ENTERPRENEURS FUND LP

VR MANAGEMENT LLC

  • 10% Owner
No longer subject to file 2013-03-15 0

VHCP CO-INVESTMENT HOLDINGS, LLC

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP MANAGEMENT, LLC

VENROCK ASSOCIATES V LP

VENROCK PARTNERS V L P

VENROCK MANAGEMENT V, LLC

VENROCK PARTNERS MANAGEMENT V, LLC

HOVE ANDERS D

  • 10% Owner
No longer subject to file 2013-03-15 0

FMR LLC

  • 10% Owner
  • EDWARD C. JOHNSON 3D
2,340,891 2012-07-09 0

RIDGEBACK CAPITAL INVESTMENTS L.P.

RIDGEBACK CAPITAL INVESTMENTS LTD.

RIDGEBACK CAPITAL MANAGEMENT LP

  • 10% Owner
No longer subject to file 2012-02-02 0

VR MANAGEMENT LLC

  • 10% Owner
42,667 2011-03-31 0

VENROCK ASSOCIATES

VENROCK ASSOCIATES II LP

VENROCK ENTERPRENEURS FUND LP

VENROCK MANAGEMENT LLC

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP CO-INVESTMENT HOLDINGS, LLC

VHCP MANAGEMENT, LLC

VR MANAGEMENT LLC

HOVE ANDERS D

  • 10% Owner
8,731,321 2010-02-02 0

MILLER GINA BORNINO

  • Director
770,952 2010-02-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

DREYFUS ANDREW - Director

2020-09-17 16:12:51 -0400 2020-09-15 A 1,600 a 112,003 direct

MCHUGH JULIE - Director

2020-09-09 18:26:27 -0400 2020-09-08 S 7,950 $9.77 d 123,107 direct yes 1.3542 3.2292 5.7292 4 0.0 1

RICKARD JASON - Officer SVP, CHIEF OPERATING OFFICER

2020-08-19 16:05:13 -0400 2020-08-17 S 689 $10.14 d 235,776 direct -2.0696 -3.9511 0.0 1 -3.9511 6

MACDONALD KELLY - Officer CHIEF ACCOUNTING OFFICER

2020-08-19 16:01:44 -0400 2020-08-17 S 575 $10.14 d 118,552 direct -2.0696 -3.9511 0.0 1 -3.9511 6

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments